June 8, 2022

Better CV Outcomes in T2D Patients Using First-Line SGLT-2is

Metformin is widely recommended as the first-line treatment for type 2 diabetes (T2D). A new study questions whether that is the best choice for patients with both T2D and cardiovascular (CV) disease, or who are at increased risk for CV events. Find out how patients fared when they initiated a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) instead of metformin.


Common Prostate Cancer Drugs Have Unexpected Adverse Effects

The population studied in clinical trials leading to drug approvals is often quite different from that in real-world settings. That may explain why two prostate cancer drugs showed few safety issues initially but now are raising concerns about their apparent connection with metabolic or cardiovascular issues. Learn more about what pharmacists should be aware of.

SARS-CoV-2 Vaccination Reduces the Risk of "Long COVID"

Here is another reason that vaccination against COVID-19 is so important: Not only do the shots reduce transmission, the risk of having a serious case, or even dying, but they are also somewhat protective against the development of long COVID. In fact, vaccinated patients appear to be most protected against two dangerous manifestations: lung and blood-clotting disorders. Read more.


What Are the Barriers to Biosimilar Use in Oncology?

Insurance coverage—or the lack thereof—is reported to be the biggest barrier to the use of biosimilars in oncology. What are some of the barriers that pharmacists have to face? Hint: a lack of patient acceptance is not a significant problem. Learn more about what a recent study from the Roswell Park Cancer Institute reveals on biosimilar barriers.

Facebook   Twitter   USP Google App   USP itunes App
U.S. Pharmacist
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Advertisement Advertisement